These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3372024)

  • 1. In vitro activity of flomoxef in comparison to other cephalosporins.
    Simon C; Simon M; Plieth C
    Infection; 1988; 16(2):131-4. PubMed ID: 3372024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of flomoxef and cefazolin in combination with vancomycin.
    Simon C; Simon M
    Infection; 1991; 19 Suppl 5():S276-8. PubMed ID: 1783443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of the new oxacephem antibiotic, flomoxef (6315-S).
    Ruckdeschel G; Eder W
    Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):687-91. PubMed ID: 3143586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of flomoxef compared to moxalactam, cefoxitin, cefotaxime, and clindamycin against anaerobes.
    Werner H; Heizmann W; Luft G
    Arzneimittelforschung; 1988 Nov; 38(11):1553-6. PubMed ID: 3214438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flomoxef showed excellent in vitro activity against clinically important gram-positive and gram-negative pathogens causing community- and hospital-associated infections.
    Yang Q; Zhang H; Cheng J; Xu Z; Hou X; Xu Y
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):269-74. PubMed ID: 25641126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
    Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
    Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antibacterial activity of FK037, a new parenteral broad-spectrum cephalosporin, against recent clinical isolates in the fields of obstetrics and gynecology.
    Mikamo H; Izumi K; Ito K; Katoh N; Watanabe K; Ueno K; Tamaya T
    Chemotherapy; 1994; 40(3):161-6. PubMed ID: 8205934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of cefonicid compared to other antibiotics against clinical bacterial isolates.
    Verbist L; Verhaegen J
    Acta Clin Belg; 1990; 45(2):113-9. PubMed ID: 2164309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefotetan: antimicrobial activity in-vitro compared with that of cefotaxime.
    Dette GA; Knothe H; Henckel S
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():11-7. PubMed ID: 6302064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in vitro activity of flomoxef compared to four other cephalosporins and imipenem.
    Shah PM; Knothe H
    Infection; 1991; 19 Suppl 5():S279-83. PubMed ID: 1783444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
    Ednie L; Shapiro S; Appelbaum PC
    Diagn Microbiol Infect Dis; 2007 May; 58(1):133-6. PubMed ID: 17240107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the in-vitro antibacterial activity of Sch 34343.
    Adam C; Naples L; Weiss W; Sabatelli F; Hare R; Loebenberg D; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():39-56. PubMed ID: 3875604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties.
    Kays MB; White RL; Friedrich LV; Del Bene VE
    Clin Ther; 1991; 13(5):596-605. PubMed ID: 1799917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of cefmetazole compared with those of other cephalosporins.
    Schell RF; Kurzynski TA; Le Frock JL; Donato JB
    Chemotherapy; 1986; 32(5):431-8. PubMed ID: 3463448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.
    Johnson DM; Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):181-8. PubMed ID: 1396735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro antibacterial activity of cefotetan.
    Grassi GG; Alesina R; Ferrara A; Peona V
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():45-58. PubMed ID: 6573325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative in-vitro activity of cefotetan against anaerobic bacteria.
    Watt B; Brown FV
    J Antimicrob Chemother; 1985 Jun; 15(6):671-7. PubMed ID: 3861604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity and beta-lactamase stability of RU29246, the active metabolite of HR916B.
    Yu KW; Chin NX; Neu HC
    Eur J Clin Microbiol Infect Dis; 1992 Jul; 11(7):652-9. PubMed ID: 1396779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens.
    Scriver SR; Willey BM; Low DE; Simor AE
    Eur J Clin Microbiol Infect Dis; 1992 Jul; 11(7):646-52. PubMed ID: 1396778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.